BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Marino P, Touzani R, Perrier L, Rouleau E, Kossi DS, Zhaomin Z, Charrier N, Goardon N, Preudhomme C, Durand-Zaleski I, Borget I, Baffert S; NGSEco Group:. Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: a nationwide French study. Eur J Hum Genet 2018;26:314-23. [PMID: 29367707 DOI: 10.1038/s41431-017-0081-3] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 8.5] [Reference Citation Analysis]
Number Citing Articles
1 Fahr P, Buchanan J, Wordsworth S. A Review of the Challenges of Using Biomedical Big Data for Economic Evaluations of Precision Medicine. Appl Health Econ Health Policy 2019;17:443-52. [PMID: 30941659 DOI: 10.1007/s40258-019-00474-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
2 Palmieri G, Rozzo CM, Colombino M, Casula M, Sini MC, Manca A, Pisano M, Doneddu V, Paliogiannis P, Cossu A. Are Molecular Alterations Linked to Genetic Instability Worth to Be Included as Biomarkers for Directing or Excluding Melanoma Patients to Immunotherapy? Front Oncol 2021;11:666624. [PMID: 34026645 DOI: 10.3389/fonc.2021.666624] [Reference Citation Analysis]
3 Pedrini E, Negro A, Di Brino E, Pecoraro V, Sculco C, Abelli E, Gnoli M, Magrelli A, Sangiorgi L, Cicchetti A. Real-World Data and Budget Impact Analysis (BIA): Evaluation of a Targeted Next-Generation Sequencing Diagnostic Approach in Two Orthopedic Rare Diseases. Front Pharmacol 2022;13:785705. [DOI: 10.3389/fphar.2022.785705] [Reference Citation Analysis]
4 Orrù G, Carta MG, Bramanti A. Design of FRET Probes for SNP RS1006737, Related to Mood Disorder. Clin Pract Epidemiol Ment Health 2018;14:53-62. [PMID: 29541152 DOI: 10.2174/1745017901814010053] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Torres S, González Á, Cunquero Tomas AJ, Calabuig Fariñas S, Ferrero M, Mirda D, Sirera R, Jantus-Lewintre E, Camps C. A profile on cobas® EGFR Mutation Test v2 as companion diagnostic for first-line treatment of patients with non-small cell lung cancer. Expert Rev Mol Diagn 2020;20:575-82. [PMID: 32011193 DOI: 10.1080/14737159.2020.1724094] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
6 Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, Normanno N, Scarpa A, Robson M, Meric-Bernstam F, Wagle N, Stenzinger A, Bonastre J, Bayle A, Michiels S, Bièche I, Rouleau E, Jezdic S, Douillard JY, Reis-Filho JS, Dienstmann R, André F. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol 2020;31:1491-505. [PMID: 32853681 DOI: 10.1016/j.annonc.2020.07.014] [Cited by in Crossref: 87] [Cited by in F6Publishing: 98] [Article Influence: 43.5] [Reference Citation Analysis]
7 Miao X, Li B, Shen Y, Yu H, Zhu G, Liang C, Fu X, Wang C, Li S, Zhang B. Development and Verification of an Economical Method of Custom Target Library Construction. ACS Omega 2020;5:13087-95. [PMID: 32548494 DOI: 10.1021/acsomega.0c01014] [Reference Citation Analysis]
8 Horiuchi S, Saito Y, Matsui A, Takahashi N, Ikeya T, Hoshi E, Shimizu Y, Yasuda M. A novel loop‑mediated isothermal amplification method for efficient and robust detection of EGFR mutations. Int J Oncol 2020;56:743-9. [PMID: 32124949 DOI: 10.3892/ijo.2020.4961] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
9 Morganti S, Tarantino P, Ferraro E, D'Amico P, Viale G, Trapani D, Duso BA, Curigliano G. Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life. Crit Rev Oncol Hematol 2019;133:171-82. [PMID: 30661654 DOI: 10.1016/j.critrevonc.2018.11.008] [Cited by in Crossref: 41] [Cited by in F6Publishing: 29] [Article Influence: 10.3] [Reference Citation Analysis]
10 Hussen BM, Abdullah ST, Salihi A, Sabir DK, Sidiq KR, Rasul MF, Hidayat HJ, Ghafouri-Fard S, Taheri M, Jamali E. The emerging roles of NGS in clinical oncology and personalized medicine. Pathol Res Pract 2022;230:153760. [PMID: 35033746 DOI: 10.1016/j.prp.2022.153760] [Reference Citation Analysis]
11 Gao G, Smith DI. Clinical Massively Parallel Sequencing. Clin Chem 2020;66:77-88. [PMID: 31811004 DOI: 10.1373/clinchem.2019.303305] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Morganti S, Tarantino P, Ferraro E, D’amico P, Viale G, Trapani D, Duso BA, Curigliano G. Role of Next-Generation Sequencing Technologies in Personalized Medicine. In: Pravettoni G, Triberti S, editors. P5 eHealth: An Agenda for the Health Technologies of the Future. Cham: Springer International Publishing; 2020. pp. 125-54. [DOI: 10.1007/978-3-030-27994-3_8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Zhang W, Zhang Z, Krushkal J, Liu A. Group testing can improve the cost-efficiency of prospective-retrospective biomarker studies. BMC Med Res Methodol 2021;21:55. [PMID: 33740890 DOI: 10.1186/s12874-021-01239-4] [Reference Citation Analysis]
14 Okonkwo A, Rimmer V, Walkden A, Brahma A, Carley F, Mcbain AJ, Radhakrishnan H. Next-Generation Sequencing of the Ocular Surface Microbiome: In Health, Contact Lens Wear, Diabetes, Trachoma, and Dry Eye. Eye & Contact Lens: Science & Clinical Practice 2020;46:254-61. [DOI: 10.1097/icl.0000000000000697] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Song W, Platteel I, Suurmeijer AJH, van Kempen LC. Diagnostic yield of NanoString nCounter FusionPlex profiling in soft tissue tumors. Genes Chromosomes Cancer 2020;59:318-24. [PMID: 31965673 DOI: 10.1002/gcc.22834] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
16 Marchetti A, Di Lorito A, Felicioni L, Buttitta F. An innovative diagnostic strategy for the detection of rare molecular targets to select cancer patients for tumor-agnostic treatments. Oncotarget 2019;10:6957-68. [PMID: 31857850 DOI: 10.18632/oncotarget.27343] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Franczak C, Dubouis L, Gilson P, Husson M, Rouyer M, Demange J, Leroux A, Merlin JL, Harlé A. Integrated routine workflow using next-generation sequencing and a fully-automated platform for the detection of KRAS, NRAS and BRAF mutations in formalin-fixed paraffin embedded samples with poor DNA quality in patients with colorectal carcinoma. PLoS One 2019;14:e0212801. [PMID: 30811471 DOI: 10.1371/journal.pone.0212801] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
18 Hofman P, Rouleau E, Sabourin JC, Denis M, Deleuze JF, Barlesi F, Laurent-Puig P. Predictive molecular pathology in non-small cell lung cancer in France: The past, the present and the perspectives. Cancer Cytopathol 2020;128:601-10. [PMID: 32885912 DOI: 10.1002/cncy.22318] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
19 Perdrizet K, Stockley TL, Law JH, Smith A, Zhang T, Fernandes R, Shabir M, Sabatini P, Youssef NA, Ishu C, Li JJ, Tsao M, Pal P, Cabanero M, Schwock J, Ko HM, Boerner S, Ruff H, Shepherd FA, Bradbury PA, Liu G, Sacher AG, Leighl NB. Integrating comprehensive genomic sequencing of non-small cell lung cancer into a public healthcare system. Cancer Treatment and Research Communications 2022. [DOI: 10.1016/j.ctarc.2022.100534] [Reference Citation Analysis]
20 Normanno N, Apostolides K, de Lorenzo F, Beer PA, Henderson R, Sullivan R, Biankin AV, Horgan D, Lawler M. Cancer Biomarkers in the era of precision oncology: Addressing the needs of patients and health systems. Semin Cancer Biol 2021:S1044-579X(21)00214-5. [PMID: 34389490 DOI: 10.1016/j.semcancer.2021.08.002] [Reference Citation Analysis]
21 Galyean S, Sawant D, Shin AC. Personalized Nutrition for Management of Micronutrient Deficiency-Literature Review in Non-bariatric Populations and Possible Utility in Bariatric Cohort. Obes Surg 2020;30:3570-82. [PMID: 32564308 DOI: 10.1007/s11695-020-04762-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Laviolle B, Denèfle P, Gueyffier F, Bégué É, Bilbault P, Espérou H, Gaillard-bigot F, Grenet G, Guérin J, Guillot C, Longeray P, Morere J, Perche O, Perrier L, Sanlaville D, Thevenon J, Varoqueaux N. The contribution of genomics in the medicine of tomorrow, clinical applications and issues. Therapies 2019;74:9-15. [DOI: 10.1016/j.therap.2018.11.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
23 Pisapia P, Pepe F, Baggi A, Barberis M, Galvano A, Gristina V, Mastrilli F, Novello S, Pagni F, Pasini S, Perrone G, Righi D, Russo A, Troncone G, Malapelle U. Next generation diagnostic algorithm in non-small cell lung cancer predictive molecular pathology: The KWAY Italian multicenter cost evaluation study. Crit Rev Oncol Hematol 2021;169:103525. [PMID: 34813925 DOI: 10.1016/j.critrevonc.2021.103525] [Reference Citation Analysis]
24 Cohen D, Hondelink LM, Solleveld-Westerink N, Uljee SM, Ruano D, Cleton-Jansen AM, von der Thüsen JH, Ramai SRS, Postmus PE, Graadt van Roggen JF, Hoppe BPC, Clahsen PC, Maas KW, Ahsmann EJM, Ten Heuvel A, Smedts F, van Rossem RN, van Wezel T. Optimizing Mutation and Fusion Detection in NSCLC by Sequential DNA and RNA Sequencing. J Thorac Oncol 2020;15:1000-14. [PMID: 32014610 DOI: 10.1016/j.jtho.2020.01.019] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 9.0] [Reference Citation Analysis]
25 Gallon R, Sheth H, Hayes C, Redford L, Alhilal G, O'Brien O, Spiewak H, Waltham A, McAnulty C, Izuogu OG, Arends MJ, Oniscu A, Alonso AM, Laguna SM, Borthwick GM, Santibanez-Koref M, Jackson MS, Burn J. Sequencing-based microsatellite instability testing using as few as six markers for high-throughput clinical diagnostics. Hum Mutat 2020;41:332-41. [PMID: 31471937 DOI: 10.1002/humu.23906] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
26 Siamoglou S, Karamperis K, Mitropoulou C, Patrinos GP. Costing Methods as a Means to Measure the Costs of Pharmacogenomics Testing. J Appl Lab Med 2020;5:1005-16. [PMID: 32916714 DOI: 10.1093/jalm/jfaa113] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Gordon LG, White NM, Elliott TM, Nones K, Beckhouse AG, Rodriguez-Acevedo AJ, Webb PM, Lee XJ, Graves N, Schofield DJ. Estimating the costs of genomic sequencing in cancer control. BMC Health Serv Res 2020;20:492. [PMID: 32493298 DOI: 10.1186/s12913-020-05318-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
28 Gallon R, Gawthorpe P, Phelps RL, Hayes C, Borthwick GM, Santibanez-Koref M, Jackson MS, Burn J. How Should We Test for Lynch Syndrome? A Review of Current Guidelines and Future Strategies. Cancers (Basel) 2021;13:406. [PMID: 33499123 DOI: 10.3390/cancers13030406] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
29 van de Ven M, Koffijberg H, Retèl V, Monkhorst K, Smit E, van Harten W, IJzerman M. Real-World Utilization of Biomarker Testing for Patients with Advanced Non-Small Cell Lung Cancer in a Tertiary Referral Center and Referring Hospitals. J Mol Diagn 2021;23:484-94. [PMID: 33493663 DOI: 10.1016/j.jmoldx.2021.01.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
30 Zischke J, White N, Gordon L. Accounting for Intergenerational Cascade Testing in Economic Evaluations of Clinical Genomics—A Scoping Review. Value in Health 2021. [DOI: 10.1016/j.jval.2021.11.1353] [Reference Citation Analysis]
31 Bekaii-Saab TS, Bridgewater J, Normanno N. Practical considerations in screening for genetic alterations in cholangiocarcinoma. Ann Oncol 2021;32:1111-26. [PMID: 33932504 DOI: 10.1016/j.annonc.2021.04.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
32 Pasmans CTB, Tops BBJ, Steeghs EMP, Coupé VMH, Grünberg K, de Jong EK, Schuuring EMD, Willems SM, Ligtenberg MJL, Retèl VP, van Snellenberg H, de Bruijn E, Cuppen E, Frederix GWJ. Micro-costing diagnostics in oncology: from single-gene testing to whole- genome sequencing. Expert Rev Pharmacoecon Outcomes Res 2021;21:413-4. [PMID: 33852815 DOI: 10.1080/14737167.2021.1917385] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
33 Coquerelle S, Darlington M, Michel M, Durand M, Borget I, Baffert S, Marino P, Perrier L, Durand-Zaleski I; NGSEco Group. Impact of Next Generation Sequencing on Clinical Practice in Oncology in France: Better Genetic Profiles for Patients Improve Access to Experimental Treatments. Value Health 2020;23:898-906. [PMID: 32762992 DOI: 10.1016/j.jval.2020.03.005] [Reference Citation Analysis]
34 Wang HY, Chen CH, Shi S, Chung CR, Wen YH, Wu MH, Lebowitz MS, Zhou J, Lu JJ. Improving Multi-Tumor Biomarker Health Check-up Tests with Machine Learning Algorithms. Cancers (Basel) 2020;12:E1442. [PMID: 32492934 DOI: 10.3390/cancers12061442] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
35 Jiang X, Zhao C, Fan X, Xu W, Zhang R, Xu H, Wu G. A DNA-modified hydrogel for simultaneous purification, concentration and detection of targeted cfDNA in human serum. RSC Adv 2019;9:3407-15. [DOI: 10.1039/c8ra10138h] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]